Your GLP-1 Is Doing More to Your Brain Than You Think

Your brain runs on a reward system, and that system runs on dopamine, and dopamine is not just about pleasure. It is about wanting. It is the chemical that makes you reach for your phone, pursue a goal, initiate sex, open the fridge. Dopamine is what makes you do things before you get the reward, not after. And GLP-1 drugs are reaching directly into the circuitry that produces it.

Most people think of these drugs as appetite suppressants. That is not wrong, but it is incomplete. The mechanism that reduces your hunger is the same mechanism that reduces your drive toward everything else your brain has been trained to want.

Here is the full pathway. When you eat, or when you anticipate something pleasurable, a region deep in your brainstem called the ventral tegmental area fires dopamine into your forebrain. That signal is what creates craving, pursuit, and motivation. The ventral tegmental area does not work in isolation though. It has gatekeepers, which are a class of neurons that use something called GABA, which is the brain's primary inhibitory signal, to regulate how much dopamine actually gets released. Think of the dopamine neurons as a factory floor and the GABA neurons as the manager deciding how fast the line runs. GLP-1 receptors sit on those GABA managers, right inside the ventral tegmental area, and when a GLP-1 drug activates those receptors, it tells the managers to work harder, which slows the factory floor, which means less dopamine release into the system.

A 2025 study published in Science Advances confirmed this directly, showing that GLP-1 receptor activation in the ventral tegmental area increases GABA neuron firing, suppresses dopamine neuron activity, and reduces reward-seeking behavior. That is the circuit. That is why the drugs reduce your drive toward food, alcohol, and sex through the same underlying mechanism.

Now here is where it gets specific in a way most people miss. There is a distinction researchers make between two components of desire that are actually processed by different brain circuits. One is called wanting, which is the motivated drive to pursue something. The other is called liking, which is the hedonic pleasure you experience when you actually get it. These feel like the same thing from the inside, but they are biologically separate, and GLP-1 drugs appear to target wanting while leaving liking mostly intact.

A 2025 study in Neurobiology of Disease and Treatment found that semaglutide reduced reward-seeking behavior but did not reduce the hedonic response once the reward was received. The drug actually appeared to enhance dopamine activity during the consummatory phase, meaning the moment of getting the thing felt normal or possibly even slightly better, while the drive to go get it was suppressed.

This is the pharmacological reason people do not notice the change while it is happening. If the drug made sex feel bad, you would notice immediately. But because the act still feels good, your brain never registers that anything is wrong. What has changed is the approach behavior, the initiation, the spontaneous desire that would have moved you toward it in the first place. And because nothing in your present-moment experience signals a problem, there is no alarm.

That is exactly what makes this hard to detect without an outside perspective.

On top of the dopamine pathway, a 2026 clinical review published in Obesity Pillars proposed a second mechanism working in parallel. GLP-1 drugs appear to increase activity at something called the 5-HT2C receptor, which is a serotonin receptor subtype, and the same one that is implicated in the sexual side effects of SSRIs like reduced libido and delayed arousal. This is still a proposed mechanism rather than a confirmed one, but if it holds up, it means two separate pathways are reducing desire simultaneously, one through dopamine suppression in the reward circuit and one through serotonin activity that independently downregulates sexual motivation.

The review also points out something important about why this effect stays hidden in clinical practice. People on GLP-1 drugs are usually losing weight, and weight loss tends to improve mood, energy, and body image, all of which typically improve sexual desire. So the positive effects of the weight loss can mask the suppressive effects of the drug on the reward system, and the net result looks neutral or even positive on questionnaires. The suppression is there, but it is getting competed out by the confounding variable.

The alcohol data reinforces the picture. A 2025 randomized clinical trial in JAMA Psychiatry with 48 participants found that once-weekly semaglutide significantly reduced alcohol consumption, cravings, and heavy drinking days in adults with alcohol use disorder. Alcohol is one of the most dopamine-activating substances humans consume, and the fact that semaglutide reduces the craving for it is direct evidence that the reward pathway modulation is real and broad, not limited to food.

On the reversibility side, one 2024 placebo-controlled crossover trial of dulaglutide in healthy men over four weeks showed no significant change in sexual function scores. Dulaglutide is a GLP-1 agonist with weaker central nervous system penetration than semaglutide, and four weeks may be too short a window to capture the shift, especially given that some of the confounding improvements in wellbeing would be operating in the other direction during that same window. The null result from that study is worth knowing but probably does not close the question.

For people who do want to come off and reset: GLP-1 agonists like semaglutide have a half-life of roughly one week, which means after four to five half-lives, approximately four to five weeks, the drug is largely cleared and receptor signaling returns toward baseline. The reversal of these effects appears to follow the same timeline.

The reason this matters beyond sex drive is that wanting is the engine of almost everything you do. It is what makes you want to train, to build something, to connect with people, to care about outcomes. GLP-1 drugs are not just removing your appetite for food. They are turning down the volume on the part of your brain that makes you reach toward anything.

That is not an argument against the drugs. It is just what is actually happening, and most people taking them were never told.

---

References

1. Merkel R, Thapa N, Engel L, et al. 2025. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Science Advances, 119, eadr5051. Finding: GLP-1 receptor activation in the VTA increases GABA neuron firing, which suppresses dopamine neuron activity and reduces reward-seeking behavior. Source
2. Hurst K, et al. 2025. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neurobiology of Disease and Treatment. Finding: Semaglutide reduced reward collection but did not diminish hedonic "liking" response, and actually enhanced VTA dopamine activity during consummatory phase. Source
3. Gelfand SG, Tveit RL, Simon JA. 2026. Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it. Obesity Pillars, 17, 100233. Finding: GLP-1 agonists likely decrease sexual desire via 5-HT2C serotonergic upregulation same mechanism as SSRIs, but this is camouflaged by competing positive effects of weight loss. Source
4. Hendershot CS, et al. 2025. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 824, 395-405. Finding: Semaglutide reduced alcohol consumption, craving, and heavy drinking days in a Phase 2 RCT n=48, confirming reward pathway modulation extends beyond appetite. Source
5. Jalleh RJ, et al. 2024. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. eBioMedicine, 107. Finding: 4-week dulaglutide in healthy eugonadal men showed no change in sexual function scores null result, but short duration and weaker CNS penetration than semaglutide. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness